Seer Appoints Meeta Gulyani to its Board of Directors
November 29 2021 - 4:05PM
Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing
a disruptive new platform for proteomics, today announced it has
appointed Meeta Gulyani to serve on its Board of Directors. Ms.
Gulyani is currently Executive Vice President, Head of Strategy,
Business Development and Transformation for the Life Science
business of Merck KGaA, Darmstadt, Germany, a global science and
technology company, which operates as MilliporeSigma in the U.S.
and Canada.
“Meeta is a seasoned life sciences and pharma leader with global
experience across markets, including Asia, an important market for
Seer, and we are really pleased to welcome Meeta to our Board,”
said Omid Farokhzad, M.D., Chair, Chief Executive Officer and
Founder of Seer. “Meeta’s experience, expertise and passion for
innovation in healthcare will be an asset to the Seer Board and
accelerating our mission of opening up a new gateway to the
proteome.”
“I am honored to join the Seer Board and excited to contribute
to the company’s mission,” said Ms. Gulyani. “Seer is redefining
what’s possible in proteomics, creating a path to drive new
insights and revolutionize our understanding of biology – it truly
is the next frontier in human health. I look forward to partnering
with the Seer team to accelerate this incredible
transformation."
In her current role as Head of Strategy, Business Development
and Transformation for the Life Science business of Merck KGaA,
Darmstadt, Germany, Meeta leads the development of the Life Science
sector strategy and searches out and delivers deals of value to
enable the achievement of its growth ambition. Meeta was previously
Executive Vice President and Head of Strategy and Global Franchises
for the Biopharma business of Merck KGaA, Darmstadt, Germany. Prior
to that, she served as General Manager for Roche South Asia, and
Vice President, Head of Global Portfolio Management at Roche. Prior
to Roche, Meeta held several marketing and sales leadership
positions within Sanofi. She also served as a strategy consultant
with the Monitor Consulting Group based in Hong Kong and the United
States. Meeta holds a M.B.A. from the Asian Institute of
Management, Philippines, accompanied by an exchange program at the
Wharton School of the University of Pennsylvania. She earned a
bachelor’s degree in economics from the Shri Ram College of
Commerce at Delhi University in India.
About Seer Inc.
Seer™ is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer is
commercializing its Proteograph™ Product Suite, an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Investor ContactCarrie
Mendivilinvestor@seer.bio
Media ContactKaren Possematopr@seer.bio
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1f74c338-98e5-4435-b55a-5e0a15dec7a4
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024